"Both pelabresib and CPI-0209 have broad potential, and we look forward to unlocking their full benefits for cancer patients," said MorphoSys CEO Jean-Paul Kress. Last year, MorphoSys won accelerated approval for Monjuvi in combination with Revlimid for treating diffuse large B-cell lymphoma. Now what Constellation's share price is nearly at the $34 offered by MorphoSys, so the small biotech stock won't move much higher.